New diagnostic test for bladder cancer
Links shared publicly online about this topic.
- 1,069total visits
New diagnostic test for bladder cancer
View full resource at physorg.com
Tags: Cancer, Bladder Cancer, Urinary System, Hospital, Hospitals
Most Recently Shared on June 25, 2010 at 10:41 am By:
New diagnostic test for bladder cancer http://bit.ly/bphtxt
Study confirms value of Cambridge Heart's MTWA test for SCA
news-medical.net — “Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that a new study published on-line in the Heart Rhythm Journal confirms the value of Microvolt T-Wave Alternans (MTWA) testing for identifying patients at risk of sudden cardiac arrest.” View full resource at news-medical.net
Most Recently Shared on March 19, 2012 at 1:53 pm By:
HIV/AIDS News: Study confirms value of Cambridge Heart's MTWA test for SCA: Cambridge Heart, Inc., a developer o... http://t.co/NaMWbABV
'Biopsy In A Blood Test' - Effective New Diagnostic For Cancer
medicalnewstoday.com — “Scientists from The Scripps Research Institute, Scripps Health, and collaborating cancer physicians have successfully demonstrated the effectiveness of an advanced blood test for detecting and ana” View full resource at medicalnewstoday.com
Most Recently Shared on February 7, 2012 at 8:05 am By:
MNT Pancreatic Can Health News
'Biopsy In A Blood Test' - Effective New Diagnostic For Cancer http://t.co/mlGDHSwi #pancreaticcancer
Patient Care Could Be Revolutionized By Diagnostic Brain Tumor Test
medicalnewstoday.com — “Researchers at UT Southwestern Medical Center have developed what they believe to be the first clinical application of a new imaging technique to diagnose brain tumors. The unique test could precl” View full resource at medicalnewstoday.com
Most Recently Shared on January 30, 2012 at 8:05 am By:
MNT Neurology News Neurology and Health News
Patient Care Could Be Revolutionized By Diagnostic Brain Tumor Test http://t.co/fV2Q6RHy #neurology
Gene test may aid early-stage lung cancer patients
sfgate.com — “In a finding that could improve the survival odds for early-stage lung cancer patients, UCSF researchers have determined a new molecular test can predict more accurately than current diagnostic methods which tumors are...” View full resource at sfgate.com
Most Recently Shared on January 27, 2012 at 3:00 am By:
Breakthrough based on UCSF research could aid lung cancer patients http://t.co/2iHxoFdO
New Software For Analyzing Digital Pathology Separates Malignancy From Background Tissue In Bladder Cancer Test Case
medicalnewstoday.com — “As tissue slides are more routinely digitized to aid interpretation, a software program whose design was led by the University of Michigan Health System is proving its utility.In a new s” View full resource at medicalnewstoday.com
Most Recently Shared on January 14, 2012 at 8:05 am By:
New Software For Analyzing Digital Pathology Separates Malignancy From Background Tissue In Bladder Cancer Test Case http://t.co/FS7G5nXV
Qiagen Gains Approval in Japan for EGFR Companion Diagnostic, Rights to Cancer Biomarkers | IVD Technology
ivdtechnology.com — “Qiagen announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, has been shown to play an important role in certain cancers and is the target of many new anticancer drugs. The approval is a milestone in Qiagen's Personalized Healthcare strategy, as Japan is one of the world's largest markets for companion diagnostic tests.” View full resource at ivdtechnology.com
Most Recently Shared on January 10, 2012 at 6:56 pm By:
IVD Technology Health Magazine
Qiagen Gains Approval in Japan for EGFR Companion Diagnostic, Rights to Cancer Biomarkers http://t.co/L0pEGjEk
Qiagen Receives Regulatory Approval in Japan for EGFR Companion Diagnostic to Guide Cancer Treatments | Biomarker Commons
biomarkercommons.org — “Qiagen today announced the regulatory approval of its therascreen EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, has been shown to play an important role in certain cancers and is the target of many new anticancer drugs.” View full resource at biomarkercommons.org
Most Recently Shared on January 10, 2012 at 12:53 pm By:
HistoRx Licenses Assay from Yale | IVD Technology
ivdtechnology.com — “HistoRx licensed from Yale University a new clinical diagnostic assay based on AQUA technology. This assay enables doctors treating patients with melanoma to identify a subset of those patients who, despite having no detectable cancer in their lymph nodes, have a 40% risk of recurrence of their disease. AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis.” View full resource at ivdtechnology.com
Most Recently Shared on December 21, 2011 at 11:35 pm By:
IVD Technology Health Magazine
HistoRx Licenses Assay from Yale http://t.co/pe6mc2qk
Merger and acquisition activity in the global pharmaceutical industry: PwC
pwc.com — “PwC’s Diagnostics 2011 provides an overview of M&A deal activity during the past two years and the factors driving it, including the advance of personalised medicine and testing for earlier detection of diseases, such as cancer and Alzheimer’s. The report also includes an in-depth discussion about trends in companion diagnostics and business model considerations for pharmaceutical companies.” View full resource at pwc.com
Most Recently Shared on December 14, 2011 at 9:20 pm By:
RT @PwC_LLP M&A surges, companion diagnostics accelerate & early detection offers new prospects for #IVD industry http://t.co/0u1JggTJ
Merger and acquisition activity in the global pharmaceutical industry: PwC
pwc.com — “PwC’s Diagnostics 2011 provides an overview of M&A deal activity during the past two years and the factors driving it, including the advance of personalised medicine and testing for earlier detection of diseases, such as cancer and Alzheimer’s. The report also includes an in-depth discussion about trends in companion diagnostics and business model considerations for pharmaceutical companies.” View full resource at pwc.com
Most Recently Shared on December 7, 2011 at 8:30 pm By:
#PwC #Diagnostics 2011 report highlights $15billion in IVD deals in first 7 mos of '11 and factors driving M&A http://t.co/aphTI5eP
Prostate cancer diagnostic test shows promise in reducing repeat biopsies - - ModernMedicine
modernmedicine.com — “A prototype of a prostate cancer diagnostic test may help urologists distinguish patients who have a true negative biopsy from those who may have occult cancer undetected by prostate biopsy and histopathologic review, new study findings show.” View full resource at modernmedicine.com
Most Recently Shared on December 6, 2011 at 6:40 pm By:
JohnsHopkinsMedicine Health News
Prostate #cancer diagnostic test shows promise in reducing repeat biopsies http://t.co/OhAsnf2K
HealthLinx expands distribution of ovarian cancer test to Spain under new agreement - Proactiveinvestors (AU)
proactiveinvestors.com.au — “HealthLinx (ASX: HTX) has signed an agreement with Barcelona-based Oryzon Genomics for the distribution of the company’s ovarian cancer diagnostic, OvPlex™, in Spain, with an option to extend exclusive licence rights to Portugal, Andorra, France and Italy.” View full resource at proactiveinvestors.com.au
Most Recently Shared on November 23, 2011 at 2:35 am By:
Paul Cacciatore Patient Advocate
OvPlex™ ovarian cancer test 2 B distributed in Spain. http://t.co/r6Cv1sNm
Veracyte Finds a Way to Make a Buck Cutting Waste in Thyroid Cancer Treatment | Xconomy
xconomy.com — “How can a company charge $3,500 per patient for some new gee-whiz diagnostic test, and then go around claiming it will save the healthcare system money? Lots” View full resource at xconomy.com
Most Recently Shared on November 18, 2011 at 11:30 pm By:
Luke Timmerman Health Communicator
South SF-based Veracyte finds a way to make a buck by cutting waste in thyroid cancer treatment http://t.co/XfUVWTbd
NIH to Support Clinical Utility Validation of New Molecular Diagnostic Tests | Biomarker Commons
biomarkercommons.org — “The National Institutes of Health announced yesterday that the National Cancer Institute will support applications to perform validation of the clinical usefulness of new molecular diagnostics for prognosis or prediction of the response to therapy for cancer.” View full resource at biomarkercommons.org
Most Recently Shared on November 17, 2011 at 4:57 pm By:
Oryzon to Launch its First Product, GynEC Dx, a Non-invasive Test for the Detection of Endometrial Cancer | Biomarker Commons
biomarkercommons.org — “The outcome of the clinical trial for GynEC-DX, Oryzon’s first product, was presented recently at the 17th Biennial Meeting of the European Society for Gynaecological Oncology (ESGO) held in Milano (Italy).” View full resource at biomarkercommons.org
Most Recently Shared on October 7, 2011 at 11:06 am By:
Advertisement
